{"DataElement":{"publicId":"3577517","version":"1","preferredName":"Acute Myeloid Leukemia Conversion From Myelodysplastic Syndrome And/Or Myeloproliferative Neoplasm Occurrence Indicator","preferredDefinition":"The indicator that describes whether or not acute myeloid leukemia transformed from myelodysplastic and/or chronic myeloproliferative neoplasm.","longName":"3925914v1.0:2784450v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"3925914","version":"1","preferredName":"Acute Myeloid Leukemia Conversion From Myelodysplastic Syndrome And/Or Myeloproliferative Neoplasm Occurrence","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues.  The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized.  The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification).  (WHO, 2001)_The act of changing the nature, form, function, or purpose of something to another._Used to indicate a specified place or time as a starting point; used to indicate a source, cause, agent, or instrument._A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines.  The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia.  It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy.  (WHO, 2001)_Used to indicate that either or both of two items or options may be valid._A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008)_An instance of something happening, such as an event or incident.","longName":"2320063v1.0:3925912v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"3946413","version":"1","preferredName":"Acute Myeloid Leukemia Conversion","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues.  The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized.  The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification).  (WHO, 2001) -- 2003:The act of changing the nature, form, function, or purpose of something to another.","longName":"C3171:C52566","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Conversion","conceptCode":"C52566","definition":"The act of changing the nature, form, function, or purpose of something to another.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA83F3C6-A52E-E865-E040-BB89AD43526F","latestVersionIndicator":"Yes","beginDate":"2013-11-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-11-06","modifiedBy":"ONEDATA","dateModified":"2013-11-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3946414","version":"1","preferredName":"From Myelodysplastic Syndrome And/Or Myeloproliferative Neoplasm Occurrence","preferredDefinition":"Used to indicate a specified place or time as a starting point; used to indicate a source, cause, agent, or instrument.:A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001):Used to indicate that either or both of two items or options may be valid.:A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008):Occurrence; an instance of something happening.","longName":"3946414v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"From","conceptCode":"C25516","definition":"Used to indicate a specified place or time as a starting point; used to indicate a source, cause, agent, or instrument.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"And/Or","conceptCode":"C48928","definition":"Used to indicate that either or both of two items or options may be valid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Myeloproliferative Neoplasm","conceptCode":"C4345","definition":"A group of myeloid neoplasms that includes the following: chronic myeloid leukemia, BCR-ABL1 positive; polycythemia vera; essential thrombocythemia;  primary myelofibrosis; chronic neutrophilic leukemia; chronic eosinophilic leukemia, not otherwise specified; and myeloproliferative neoplasm, unclassifiable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Occurrence","conceptCode":"C25275","definition":"An instance of something happening, such as an event or incident.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA83F3C6-A542-E865-E040-BB89AD43526F","latestVersionIndicator":"Yes","beginDate":"2013-11-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-11-06","modifiedBy":"ONEDATA","dateModified":"2013-11-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E955D193-D65C-33AB-E040-BB89AD437996","latestVersionIndicator":"Yes","beginDate":"2013-10-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-22","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2784450","version":"1","preferredName":"Yes No Unk ND NA Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.","longName":"Y_N_U_ND_NA_IND","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"25","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"2567168","version":"1","preferredName":"Yes","longName":"2567168","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D36D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":"12/29/2006 - Updated with NCI Thesaurus definition.","administrativeNotes":"2022.12.29 Alt VM added per ticket request CADSR0001837. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"56A428C5-E072-6CDD-E044-0003BA3F9857","beginDate":"2008-09-11","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-09-11","modifiedBy":"ALEYR","dateModified":"2008-09-11","deletedIndicator":"No"},{"value":"No","valueDescription":"No ","ValueMeaning":{"publicId":"2567170","version":"1","preferredName":"No","longName":"2567170","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D36F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-13","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":"Updated to add NCIt concept relationship. Updated VM Short Name to be the Public ID to be consistent with current convention for VM Short Name - DW 10-03-2022","administrativeNotes":"2022.12.29 Alt VM added per ticket request CADSR0001837. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"56A428C5-E07E-6CDD-E044-0003BA3F9857","beginDate":"2008-09-11","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-09-11","modifiedBy":"ALEYR","dateModified":"2008-09-11","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"2565695","version":"1","preferredName":"Unknown","longName":"2565695","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-CDAC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-02-26","endDate":null,"createdBy":"MEDVEDOH","dateCreated":"2003-02-26","modifiedBy":"MMADDINENI","dateModified":"2024-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"56A428C5-E08A-6CDD-E044-0003BA3F9857","beginDate":"2008-09-11","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-09-11","modifiedBy":"ALEYR","dateModified":"2008-09-11","deletedIndicator":"No"},{"value":"Not Applicable","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"56A428C5-E0A2-6CDD-E044-0003BA3F9857","beginDate":"2008-09-11","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-09-11","modifiedBy":"ALEYR","dateModified":"2008-09-11","deletedIndicator":"No"},{"value":"Not Done","valueDescription":"Not Done: C49484","ValueMeaning":{"publicId":"2579172","version":"1","preferredName":"Not Done: C49484","longName":"2579172","preferredDefinition":"Indicates a task, process or examination that has either not been initiated or completed.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Done","conceptCode":"C49484","definition":"Indicates a task, process or examination that has either not been initiated or not been completed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0251-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-05-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-05-04","modifiedBy":"KUMMEROA","dateModified":"2022-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"59223A59-341F-0A9E-E044-0003BA3F9857","beginDate":"2008-09-11","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-10-13","modifiedBy":"ALEYR","dateModified":"2008-10-13","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2784449","version":"1","preferredName":"Yes No Unknown Not Done Not Applicable Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Not known, not observed, not recorded, or refused.:Indicates a task, process or examination that has either not been initiated or completed.:Determination that a value is not relevant in the current context.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"C49488:C49487:C17998:C49484:C4","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Done","conceptCode":"C49484","definition":"Indicates a task, process or examination that has either not been initiated or not been completed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"56A428C5-E04C-6CDD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-09-11","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-09-11","modifiedBy":"ONEDATA","dateModified":"2008-09-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"56A428C5-E05D-6CDD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-09-11","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-09-11","modifiedBy":"GDEEN","dateModified":"2023-05-12","changeDescription":". Modified def to preferred def per caDSR meeting. No versioning needed. AK 2/8/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"PreTed_prime_dis_hct_aml_transform_mds_mps_yn","type":"NMDP_FN","context":"NHLBI"},{"name":"TDIS_AML_transform_mds_mps_yn","type":"NMDP_FN","context":"NHLBI"},{"name":"COG","type":"USED_BY","context":"COG"},{"name":"MDS_TRNSF_AML_DX_IND","type":"Context Short Name","context":"COG"}],"ReferenceDocuments":[{"name":"Did acute myeloid leukemia co","type":"Preferred Question Text","description":"Did acute myeloid leukemia convert from myelodysplastic and or chronic myeloproliferative neoplasm?","url":null,"context":"NHLBI"},{"name":"Did AML transform from MDS or MPN?","type":"Alternate Question Text","description":"Did AML transform from MDS or MPN?","url":null,"context":"NHLBI"},{"name":"Did AML transform from MDS or MPN?","type":"Application Standard Question Text","description":"Did AML transform from MDS or MPN?","url":null,"context":"NHLBI"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Was this MDS that transformed to AML at diagnosis?","url":null,"context":"COG"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C895425C-9AFB-3F19-E040-BB89AD436B55","latestVersionIndicator":"Yes","beginDate":"2012-08-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-08-31","modifiedBy":"KUMMEROA","dateModified":"2022-06-10","changeDescription":". Added human readable def. System generated def displayed as alt def. No version needed. AK 10/31/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}